Report Phase 2 proof-of-concept data for the Z-AAT corrector VX-864

Delivered by the deadline

AI-confirmed · human review in progress Independent AI checks agreed on primary SEC or regulator evidence. Records are now being reviewed by hand, starting with those our customers order.

Announced: 29 Oct 2020
Due: 30 Jun 2021

Deadline
Met
Late
Not met
Today

What the company said

“we look forward to the VX-864 Phase 2 proof-of-concept data in the first half of 2021”

SourceVertex Pharmaceuticals Form 8-K press release, 2020-10-29
FilingSEC filing index
Deadline as statedin the first half of 2021
Deadline used30 Jun 2021, the last day of the stated period
TypeProject
Permanent referenceKI-C-2020-VRTX-006484
Cite as https://keptindex.org/c/KI-C-2020-VRTX-006484/ — this address never changes.

What we found

Evidence strength A What the grades mean

A later 10-Q states that in June 2021 the company announced it had achieved the primary endpoint and proof of mechanism for VX-864 in its Phase 2 trial, within the first-half 2021 window.

A
Vertex Pharmaceuticals 10-Q filed 2021-07-30 Regulatory filing · published 30 Jul 2021 · retrieved 10 Oct 2026 · kept permanently by the SEC
“In June, we announced that we had achieved our primary endpoint and established proof of mechanism in a Phase 2 clinical trial evaluating our Z-AAT corrector, VX-864.” ✓ confirmed on the page
A
Vertex Pharmaceuticals 10-K filed 2022-02-09 Regulatory filing · published 9 Feb 2022 · retrieved 10 Oct 2026 · kept permanently by the SEC
“In June 2021, we announced that we had achieved our primary endpoint and established proof of mechanism in a Phase 2 clinical trial evaluating our Z-AAT corrector, VX-864” ✓ confirmed on the page

Market reaction: the shares moved -0.3% against the S&P 500 over the three sessions around the disclosure (29 Jul 2021 to 3 Aug 2021). What this measures

Checked 10 Oct 2026.

Commitment lineage

Every time the company restated this commitment. The original is never changed, and the outcome is always measured against version 1.

2 versions

Version 1 · original · stated 29 Oct 2020

Deadline 30 Jun 2021 (“in the first half of 2021”)
Version 2 · stated 1 Feb 2021

Deadline 30 Jun 2021 (“in the first half of 2021”) · wording expected

“Enrollment is ongoing in a Phase 2 proof-of-concept study for the Z-AAT corrector, VX-864. Data from this study is expected in the first half of 2021.”
Source for this version

Commitment DNA

The structured record of this commitment. Fields the company did not state are left blank rather than guessed.

Event type: Clinical readout
Indicative materiality: Medium rules
Action: Report
Deliverable: VX-864 Phase 2 proof-of-concept data
In the company’s control: Medium
Specificity: High

How this entry was checked

Commitment recordedThe company's words were matched word for word against the filing.
First checkAn AI model, Claude (Anthropic), read the company's later filings and recorded the outcome with a quoted passage.
Second check: agreesA different AI model, Gemini (Google), re-read the evidence without being told the outcome and reached the same answer.

Confirmed. This outcome counts towards the company's Kept Score. How verification works

Are you Vertex Pharmaceuticals? You can publish an official statement next to this entry, free. Add a statement.

Is something here wrong or out of date? Companies and readers can ask us to check it. Please bring a link to a public source.